Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TENX
stocks logo

TENX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.417
+131.48%
--
--
-0.425
+51.79%
--
--
-0.430
+59.26%
Estimates Revision
The market is revising No Change the revenue expectations for Tenax Therapeutics, Inc. (TENX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 55.96%.
EPS Estimates for FY2025
Revise Downward
down Image
-65.92%
In Past 3 Month
Stock Price
Go Up
up Image
+55.96%
In Past 3 Month
Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 25.00 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 25.00 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.350
sliders
Low
20.00
Averages
25.00
High
30.00
Current: 9.350
sliders
Low
20.00
Averages
25.00
High
30.00
Piper Sandler
Yasmeen Rahimi
Overweight
initiated
$20
2025-09-08
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$20
2025-09-08
initiated
Overweight
Reason
Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics with an Overweight rating and $20 price target. The company is s developing TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction with the Phase 3 LEVEL readout expected in the second half of 2026, the analyst tells investors in a research note. The firm believes Tenax is "flying under the radar" despite having the potential win approval in a high unmet need indication.
Guggenheim
Seamus Fernandez
Buy
downgrade
$16 -> $15
2025-05-15
Reason
Guggenheim
Seamus Fernandez
Price Target
$16 -> $15
2025-05-15
downgrade
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tenax Therapeutics Inc (TENX.O) is -5.48, compared to its 5-year average forward P/E of -1.78. For a more detailed relative valuation and DCF analysis to assess Tenax Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.78
Current PE
-5.48
Overvalued PE
-0.40
Undervalued PE
-3.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.27
Undervalued EV/EBITDA
-0.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.41
Current PS
0.00
Overvalued PS
1.70
Undervalued PS
-0.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TENX News & Events

Events Timeline

(ET)
2025-11-12
17:19:56
Tenax Therapeutics announces Q3 earnings per share of 40 cents, falling short of consensus estimate of $1.12
select
2025-09-16 (ET)
2025-09-16
07:06:29
Tenax reveals EPO's plan to approve patent for levosimendan in PH-HFpEF
select
2025-08-13 (ET)
2025-08-13
16:15:25
Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13Yahoo Finance
Tenax Therapeutics: Overview of Q3 Earnings

  • Company Performance: Tenax Therapeutics Inc. reported a loss of $15.8 million in its third quarter, equating to a loss of 40 cents per share.

  • Market Expectations: The reported loss was better than Wall Street expectations, which anticipated a loss of $1.33 per share according to analysts surveyed by Zacks Investment Research.

[object Object]
Preview
9.5
08-14Yahoo Finance
Tenax Therapeutics: Q2 Earnings Snapshot

  • Financial Performance: Tenax Therapeutics Inc. reported a loss of $10.8 million in its second quarter, equating to 27 cents per share.

  • Market Expectations: The company's results exceeded Wall Street expectations, which anticipated a larger loss of 50 cents per share according to analysts from Zacks Investment Research.

[object Object]
Preview
8.5
04-16SeekingAlpha
Teanx Therapeutics plans secondary offering

  • Prospectus Filing: Tenax Therapeutics filed a prospectus for the resale of up to 378,346 shares of common stock and approximately 3.76 million shares issuable from pre-funded warrants, with no proceeds going to the company from this sale.

  • Recent Financial Activity: The company recently announced a $25 million private placement and has available historical earnings data and financial information.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tenax Therapeutics Inc (TENX) stock price today?

The current price of TENX is 9.35 USD — it has increased 1.74 % in the last trading day.

arrow icon

What is Tenax Therapeutics Inc (TENX)'s business?

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

arrow icon

What is the price predicton of TENX Stock?

Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 25.00 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tenax Therapeutics Inc (TENX)'s revenue for the last quarter?

Tenax Therapeutics Inc revenue for the last quarter amounts to -16.81M USD, increased 263.85 % YoY.

arrow icon

What is Tenax Therapeutics Inc (TENX)'s earnings per share (EPS) for the last quarter?

Tenax Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tenax Therapeutics Inc (TENX)'s fundamentals?

The market is revising No Change the revenue expectations for Tenax Therapeutics, Inc. (TENX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 55.96%.
arrow icon

How many employees does Tenax Therapeutics Inc (TENX). have?

Tenax Therapeutics Inc (TENX) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Tenax Therapeutics Inc (TENX) market cap?

Today TENX has the market capitalization of 58.25M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free